We are live on ! Find out more
SAM

Sectoral Asset Management Portfolio holdings

AUM $121M
1-Year Est. Return 73.47%
This Fund
S&P 500
This Quarter Est. Return
+3.78%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$151M
AUM Growth
+$23M
Cap. Flow
+$26.2M
Cap. Flow %
17.3%
Top 10 Hldgs %
42.26%
Holding
109
New
25
Increased
23
Reduced
25
Closed
15

Top Buys

Rank Stock Value
1
BCAX
Bicara Therapeutics
BCAX
+$2.4M
2
PVLA
Palvella Therapeutics
PVLA
+$2.24M
3
ZBIO
Zenas BioPharma
ZBIO
+$2.05M
4
REPL icon
Replimune Group
REPL
+$2.02M
5
TECX
Tectonic Therapeutic
TECX
+$2.01M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$2.14M
2
GILD icon
Gilead Sciences
GILD
+$1.31M
3
THC icon
Tenet Healthcare
THC
+$1.21M
4
SWTX
SpringWorks Therapeutics
SWTX
+$1.12M
5
BPMC
Blueprint Medicines
BPMC
+$994K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVBP icon
51
ArriVent BioPharma
AVBP
$1.43B
$775K 0.51%
35,580
+25,490
+253% +$529K
QURE icon
52
uniQure
QURE
$2.93B
$773K 0.51%
55,450
-2,100
-4% -$28.2K
TARS icon
53
Tarsus Pharmaceuticals
TARS
$2.6B
$751K 0.5%
18,535
+1,285
+7% +$57.8K
TRVI icon
54
Trevi Therapeutics
TRVI
$2.61B
$734K 0.48%
134,150
+52,350
+64% +$326K
MLTX icon
55
MoonLake Immunotherapeutics
MLTX
$1.62B
$713K 0.47%
15,108
– –
RDNT icon
56
RadNet
RDNT
$4.93B
$711K 0.47%
12,500
-7,500
-38% -$412K
LEGN icon
57
Legend Biotech
LEGN
$3.69B
$697K 0.46%
19,627
-16,338
-45% -$529K
BBIO icon
58
BridgeBio Pharma
BBIO
$16.1B
$695K 0.46%
16,085
– –
BOLD
59
Boundless Bio
BOLD
$56.2M
$685K 0.45%
678,574
– –
FOLD
60
DELISTED
Amicus Therapeutics
FOLD
$685K 0.45%
119,585
+12,000
+11% +$77.4K
CNC icon
61
Centene
CNC
$30.1B
$679K 0.45%
+12,500
New +$733K
OMDA
62
Omada Health Inc
OMDA
$1.17B
$631K 0.42%
+34,500
New +$597K
ASND icon
63
Ascendis Pharma A/S
ASND
$16.5B
$599K 0.4%
3,471
+1,380
+66% +$225K
CI icon
64
Cigna
CI
$76.1B
$595K 0.39%
+1,800
New +$580K
SNDX icon
65
Syndax Pharmaceuticals
SNDX
$1.73B
$593K 0.39%
+63,300
New +$697K
KMTS
66
Kestra Medical Technologies
KMTS
$1.36B
$580K 0.38%
+35,000
New +$764K
ROIV icon
67
Roivant Sciences
ROIV
$24.8B
$564K 0.37%
50,007
+1,100
+2% +$11.9K
ZLAB icon
68
Zai Lab
ZLAB
$2.06B
$554K 0.37%
15,840
-14,080
-47% -$463K
BMY icon
69
Bristol-Myers Squibb
BMY
$132B
$500K 0.33%
10,800
-8,700
-45% -$427K
HNGE
70
Hinge Health
HNGE
$5.81B
$476K 0.31%
+9,206
New +$372K
CVRX icon
71
CVRx
CVRX
$143M
$432K 0.29%
73,500
+5,000
+7% +$34.5K
PTCT icon
72
PTC Therapeutics
PTCT
$6.26B
$417K 0.28%
8,535
+185
+2% +$8.78K
INCY icon
73
Incyte
INCY
$24.9B
$413K 0.27%
6,060
-85
-1% -$5.38K
CYTK icon
74
Cytokinetics
CYTK
$10.9B
$387K 0.26%
11,723
-6,345
-35% -$221K
NBIX icon
75
Neurocrine Biosciences
NBIX
$18.7B
$372K 0.25%
2,960
+55
+2% +$6.31K
1 2
3
4 5

Similar funds

RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
WIM
Wiregrass Investment Management Thomasville, Georgia $121M AUM
MW
Merited Wealth North Bay Village, Florida $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM
AAA
AG Asset Advisory Los Angeles, California $121M AUM 10.78% 1-Year Est. Return
TGM
Tenzing Global Management San Francisco, California $121M AUM 85.62% 1-Year Est. Return

Sectoral Asset Management's Q2 2025 Portfolio in Review

As of Q2 2025, Sectoral Asset Management held 109 positions worth $151M, up 18% from $128M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Sectoral Asset Management deployed $26.2M of net new capital in Q2 2025, opening 25 new positions and adding to 23 existing holdings. Its largest new stake was Bicara Therapeutics: 201,395 shares worth $1.87M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Gilead Sciences, an estimated $1.31M trimmed.

  • Sectoral Asset Management's largest Q2 2025 buy was Bicara Therapeutics: 201,395 shares worth $1.87M.
  • Sectoral Asset Management added most to Arcus Biosciences in Q2 2025, an estimated $1.97M increase.
  • Sectoral Asset Management's biggest Q2 2025 reduction was Gilead Sciences, cutting an estimated $1.31M.
  • Sectoral Asset Management fully exited Medtronic in Q2 2025, selling an estimated $2.14M.
  • Sectoral Asset Management's ten largest holdings make up 42% of its $151M portfolio in Q2 2025.
  • Sectoral Asset Management opened 25 new positions and closed 15 in Q2 2025.
  • Sectoral Asset Management's portfolio value rose 18% quarter-over-quarter to $151M.

Based on Sectoral Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.